Global Paget’s disease Treatment Market Size study & Forecast, by Type (Bisphosphonates, Calcitonin Analogues (Salmon Calcitonin), Analgesics, Calcium, and Vitamin D Supplements), Route of Administration (Oral, Intravenous, and Topical), and End User (Hos

Global Paget’s disease Treatment Market Size study & Forecast, by Type (Bisphosphonates, Calcitonin Analogues (Salmon Calcitonin), Analgesics, Calcium, and Vitamin D Supplements), Route of Administration (Oral, Intravenous, and Topical), and End User (Hospitals, Clinics, and Others) and Regional Analysis, 2022-2029

Global Paget’s disease Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Paget’s disease, also called Osteitis deformans is a chronic bone disorder that largely occurs in pelvis, skull, spine, and legs. This condition can affect one bone or several bones. The most common symptoms are bone or joint pain. Other symptoms include swelling of joints, tenderness, or redness of the skin. The increasing prevalence of Paget’s disease and the growing number of governments sponsored awareness programs are key factors driving the market growth.

The increasing incidences of Paget’s disease is driving the global Market growth. For instance – as per National Center for Biotechnology Information – around 3 million U.S. citizen are affected by Paget’s bone disease. Moreover, as per National Organization for rare disease estimates - prevalence of Paget’s disease in the United States is estimated as 1-2 percent of the general population. Also, rise in geriatric population and growing R&D activities in healthcare sector would create lucrative growth prospectus for the market over the forecast period. However, the high cost of Paget’s disease Treatment and patent expiry of certain drugs stifle the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Paget’s disease Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising prevalence of Paget’s disease of bone and growing healthcare expenditure in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing awareness towards available treatment options for Paget’s disease in the region.

Major market player included in this report are:
Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Mylan NV
Neopharma Inc.
Allergan
Sanofi S.A.
Fresenius Kabi
Mallinckrodt Pharmaceuticals
Sun Pharmaceutical Industries Ltd.

Recent Developments:
 In March 2022, Sanofi and IGM Biosciences, Inc. announced t an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets

Global Paget’s disease Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Route of Administration, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type
Bisphosphonates
Calcitonin Analogues (Salmon Calcitonin)
Analgesics
Calcium
Vitamin D Supplements
By Route of Administration
Oral
Intravenous
Topical
By End User
Hospitals
Clinics
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Mylan NV
Neopharma Inc.
Allergan
Sanofi S.A.
Fresenius Kabi
Mallinckrodt Pharmaceuticals
Sun Pharmaceutical Industries Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.